Cardinal's pharmaceutical and specialty solutions segment distributes branded, generic, and specialty drugs and over-the-counter healthcare and consumer products. Cardinal plays a central role in the ...

Management raised fiscal 2025 EPS guidance to $7.85-$8, a $0.10 increase at the midpoint, reflecting strong Pharma performance and contributions from recent acquisitions. The company expects Q3 to be ...

Hello, and welcome to the Second Quarter Fiscal Year 2025 Cardinal Health Inc. Earnings Conference Call. My name is George, and I'll be coordinator for today's event. Please note, this conference is ...

Cardinal Health reported an increase in revenue for two of its segments, while the departure of Optimum impacted its Pharmaceuticals segment.

Cardinal Health warned Thursday that if President Donald Trump follows through with threatened tariffs next month, higher ...

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.

Cardinal Health (CAH) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.82 per share a year ago. These ...

In a report released yesterday, Stephen Baxter from Wells Fargo maintained a Hold rating on Cardinal Health (CAH – Research Report), with a ...

Morgan Stanley analyst Erin Wright maintained a Buy rating on Cardinal Health (CAH – Research Report) today and set a price target of $136.00.

Cardinal Health, Inc. CAH is scheduled to report fiscal second-quarter 2025 results on Jan. 30, before the opening bell. In ...